[ad_1]
ZIVO Bioscience, Inc. (NASDAQ:live) (“ZIVO” or the “Company”), a biotech/agritech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announced that John B. Payne, Chairman of the Board of Directors President and CEO of the company has been appointed. Mr. Payne succeeds Andrew A. Dahl.
“I am honored to serve as executive leadership of ZIVO Biosciences and look forward to serving on the company’s board for 8-1/2 years, allowing for a seamless transition,” said Mr. Payne. “2021 has been a year of tremendous progress for our company and we are proud of the steps we have taken to make progress in the biotech space, continue to develop our algal technology, build the ZIVO management team and complete our upgrades.” At Nasda Listed on the Gram Capital Market. ZIVO’s board of directors and management team will continue to focus on targeted development of our biotechnology and agritech business areas and progress towards revenue realization. ”
Speaking on behalf of ZIVO’s board of directors, Christopher Maggiore said: “We are very fortunate to have executives like John agree to these executive leadership roles. His business acumen and his track record in building and managing growth businesses are accurate” ZIVO currently required skills. With today’s announcement, we reaffirm our commitment to shareholder transparency as we advance and refine ZIVO’s business plan. ”
[ad_2]
Source link
